Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000933

Drug Information
NamePitavastatin
SynonymsCID5282452; Pitavastatin [INN]; P-872441; Itavastatin; Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt; LS-190698; AC1NR03G; ( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; Nisvastatin; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, (3R,5S,6E)-; S1759_Selleck; KS-1220; LS-74594; MolPort-006-822-984; Itavastatin calcium; Pitavastatin calcium; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-,calcium salt (2:1), (3R,5S,6E)-; Livalo; CCRIS 8652; C13334; Pitavastatin calcium (JAN); NK-104; CID5282451; Pitavastatin hemicalcium; Livalo (TN); P 872441; (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; ZINC01534965; NK 104; 147511-69-1; 2C25H23FNO4.Ca; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, (S-(R*,S*-(E)))-; Alipza; AC1NR03J; (3R,5S,6E)-7-(2-Cyclopropyl-4-(p-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; Livazo; 147526-32-7; LS-74595; NKS-104; Livalo, Pitavastatin calcium; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, calcium salt (2:1), (S-(R*,S*-(E)))-; Pitavastatin; (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate; 111GE002; D01862; AKOS005145916; calcium (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate
Trade Namelivalo
CompanyKowa Pharmaceuticals (developed with Daiichi Sankyo and Nissan)
IndicationHyperlipidaemia and mixed dyslipidaemia
[ICD9: 272, 272.0-272.4   ICD10: E78]
Approved    [1]
Hyperlipidemia
[ICD9: 272.0-272.4   ICD10: E78]
Discontinued in Phase III    [2]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-
5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,
28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1
InChIKeyVGYFMXBACGZSIL-MCBHFWOFSA-N
Canonical SMILESC1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F    
Isomeric SMILESC1CC1C2=NC3=CC=CC=C3C(=C2/C=C/[C@H](C[C@H](CC(=O)O)O)O)C4=CC=C(C=C4)F
CAS NumberCAS 147526-32-7
FormulaC25H24FNO4
PubChem Compound IDCID 5282452.
PubChem Substance IDSID 3816026.
SuperDrug ATC IDC10AA08
C10AA08
ClinicalTrials.govNCT00325780;
Target3-hydroxy-3-methylglutaryl-coenzyme A reductaseInhibitor[1][2]
HMG-CoA reductaseInhibitor[1][2]
Ref 1Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. To Reference
Ref 2Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543